CYDY - CytoDyn launches mid-stage study of leronlimab in nonalcoholic fatty liver disease

The first patient has been enrolled in a Phase 2 clinical trial evaluating CytoDyn' (CYDY) leronlimab, for the treatment of non-alcoholic steatohepatitis ((NASH)) and/or Nonalcoholic Fatty Liver Disease ((NAFLD)).As previously reported, the Company’s preclinical study demonstrated strong positive data highlighting the potential of leronlimab in treating nonalcoholic fatty liver disease ((NAFLD)), a common precursor to NASH. Inhibition of CCR5 has been shown to be effective in reducing fibrosis in animal models of NASH liver fibrosis.Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that is important in HIV infection, tumor metastases, and other diseases, including NASH.

For further details see:

CytoDyn launches mid-stage study of leronlimab in nonalcoholic fatty liver disease